Drug: Cymbalta  
Company: Eli Lilly
Total spend Q1, 2012: $46.7 million
Total spend Q1, 2011: $440,360
Watch the TV commerical here >>

Clearly, Eli Lilly ($LLY) is milking this cow for all it is worth before its patent expires. That would have happened at the end of June 2013, but the FDA extended the patent for another 6 months through its pediatric-exclusivity program after Lilly studied the effects of the antidepressant on children and adolescents. Cymbalta is Lilly's second best-selling drug, generating $3.2 billion last year behind another antidepressant, Zyprexa. In the first quarter, when this ad spend was happening, the drug brought in more than $1 billion in retail sales, says, up 7.6%, after Lilly boosted its price.


Suggested Articles

One year after its landmark Reduce-It CV outcomes trial, Amarin has new data showing its Vascepa may help halt the progress of arterial plaque.

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

In its quest to become the dominant SGLT2 diabetes med for heart failure, Jardiance is touting DPP-4 inhibitor-topping data to support its case.